Conjugating low molecular mass carbohydrates to proteins. 2. Recovery of excess ligand used in the conjugation reaction.

Methods Enzymol

Laboratory of Medicinal Chemistry, Section on Carbohydrates, National Institutes of Health, NIDDK, 8 Center Drive, Building 8, Bethesda, Maryland 20892, USA.

Published: November 2003

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0076-6879(03)01011-5DOI Listing

Publication Analysis

Top Keywords

conjugating low
4
low molecular
4
molecular mass
4
mass carbohydrates
4
carbohydrates proteins
4
proteins recovery
4
recovery excess
4
excess ligand
4
ligand conjugation
4
conjugation reaction
4

Similar Publications

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in babies across the world. Irrespective of progress in the development of RSV vaccines, effective small molecule drugs are still not available on the market. Based on our previous data we designed and synthesized triazole-linked coumarin-monoterpene hybrids and showed that they are indeed effective in inhibiting the RSV replication.

View Article and Find Full Text PDF

Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers.

View Article and Find Full Text PDF

On-site biosignal amplification using a single high-spin conjugated polymer.

Nat Commun

January 2025

National Key Laboratory of Advanced Micro and Nano Manufacture Technology, School of Materials Science and Engineering, Peking University, Beijing, China.

On-site or in-sensor biosignal transduction and amplification can offer several benefits such as improved signal quality, reduced redundant data transmission, and enhanced system integration. Ambipolar organic electrochemical transistors (OECTs) are promising for this purpose due to their high transconductance, low operating voltage, biocompatibility, and suitability for miniaturized amplifier design. However, limitations in material performance and stability have hindered their application in biosignal amplification.

View Article and Find Full Text PDF

Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.

View Article and Find Full Text PDF

The therapeutic window of antibody drug-conjugates (ADC) remains challenging due to safety issues such as interstitial lung disease (ILD) observed with specific deruxtecan-based ADCs. To avoid ILD, we designed M9140 by conjugating the maleimide-containing hydrophilic β-glucuronide linker to exatecan and our anti-CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5) specific antibody. Following repeated iv-infusion at 3 to 30 mg/kg of M9140 every 3 weeks, the pathological findings obtained in cynomolgus monkeys were confined to gastrointestinal and hematolymphoid tissues and resembled the toxicity of exatecan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!